Emily Mc Fadden, PhD
About Emily Mc Fadden, PhD
Emily Mc Fadden, PhD, is a Postdoctoral Researcher at Yale University, specializing in ribosome biogenesis and its implications in cancer and neurodegenerative diseases. She holds a PhD in Biochemistry from Duke University and has a background in tutoring and research at the University of Richmond.
Current Position at Yale University
Emily Mc Fadden serves as a Postdoctoral Researcher at Yale University since 2021. In this role, she conducts research focused on ribosome biogenesis and its implications in cancer and neurodegenerative diseases. Her work contributes to the understanding of complex biological processes and their relevance to health and disease.
Previous Experience at University of Richmond
Prior to her current position, Emily Mc Fadden held multiple roles at the University of Richmond. She worked as a Tutor Supervisor in the Academic Skills Center from 2012 to 2013, overseeing tutoring programs. Additionally, she served as a Biochemistry research student from 2010 to 2013 and as a Post-Baccalaureate Researcher in the Department of Chemistry from 2013 to 2014. During her time at the University, she also worked as an Academic Tutor, providing support to students in academic skills.
Educational Background
Emily Mc Fadden earned her Doctor of Philosophy (Ph.D.) in Biochemistry from Duke University, where she studied from 2014 to 2020. Her doctoral research focused on non-coding RNA structure and function in prostate cancer under the mentorship of Amanda Hargrove, PhD. Earlier, she obtained a Bachelor of Science (B.S.) in Biochemistry and Molecular Biology from the University of Richmond, where she studied from 2009 to 2013. In 2011, she also spent 11 months studying at the National University of Ireland, Galway.
Research Focus and Aspirations
Emily Mc Fadden's research interests include non-coding RNA and its role in cancer biology, specifically prostate cancer. At Yale University, she has expanded her research to include ribosome biogenesis and its connections to various diseases. Looking ahead, she aspires to transition into the business side of scientific research and development, aiming to bridge the gap between scientific discovery and practical application.